Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 79% Improvement Relative Risk Recovery time -11% Time to viral- 22% Favipiravir for COVID-19  Turan et al.  LATE TREATMENT Is late treatment with favipiravir beneficial for COVID-19? Retrospective 237 patients in Turkey (March 2020 - January 2021) Study compares with HCQ, results vs. placebo may differ Lower hospitalization (p=0.0012) and faster viral clearance (p=0.001) c19early.org Turan et al., The Brazilian J. Infecti.., Feb 2022 Favors favipiravir Favors HCQ

The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers

Turan et al., The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2022.102328
Feb 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Retrospective 237 low-risk healthcare workers in Turkey, 123 treated with favipiravir and 114 treated with HCQ, showing lower hospitalization and faster viral clearance with favipiravir, and similar improvement. This study is subject to substantial confounding by time because the patients in each group are from different time periods with an overall period of 10 months including the beginning of the pandemic, resulting in significant differences in variants encountered and SOC. Propensity for hospital admission may also have changed significantly.
This study is excluded in meta analysis: substantial confounding by time likely due to separation of groups in different time periods over an extended period of time.
risk of hospitalization, 79.4% lower, RR 0.21, p = 0.001, treatment 4 of 123 (3.3%), control 18 of 114 (15.8%), NNT 8.0.
recovery time, 11.0% higher, relative time 1.11, p = 0.51, treatment 123, control 114.
time to viral-, 21.6% lower, relative time 0.78, p < 0.001, treatment 123, control 114.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Turan et al., 1 Feb 2022, retrospective, Turkey, peer-reviewed, mean age 33.4, 10 authors, study period 11 March, 2020 - 1 January, 2021, this trial compares with another treatment - results may be better when compared to placebo.
This PaperFavipiravirAll
The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers
Derya Bayırlı Turan, Mehtap Menteş, Yıldıran Özel, Kıvanç Şerefhanoğlu, Burcu Aydoğan, Neşe İbil, Füsun Güneşdoğdu, Hijran Mammadova Orucova, Cüneyt Saltürk, Hakan Çelik
The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2022.102328
Objectives: Comparative data on hydroxychloroquine and favipiravir, commonly used agents in the treatment of Coronavirus Disease-2019 (COVID-19), are still limited. In this study, it was aimed to compare treatment outcomes in healthcare workers with COVID-19 who were prospectively followed by the occupational health and safety unit. Methods: A total of 237 healthcare-workers, diagnosed as mild or moderate COVID-19 between March 11, 2020 and January 1, 2021, were given hydroxychloroquine (n = 114) or favipiravir (n = 123). Clinical and laboratory findings were evaluated. Results: The mean age of the patients was 33.4 §11.5 years. The mean time to negative PCR was found to be significantly shorter in patients receiving favipiravir compared to the hydroxychloroquine group (10.9 vs. 13.9 days; p < 0.001). The rate of hospitalization in the hydroxychloroquine group was significantly higher than favipiravir group (15.8% vs. 3.3%). In terms of side effects; the frequency of diarrhea in patients receiving hydroxychloroquine was significantly higher than that in the favipiravir group (31.6% vs. 6.5%; p < 0.001). Conclusions: Favipiravir and hydroxychloroquine were similar in terms of improvement of clinical symptoms of healthcare workers with mild or moderate COVID-19 infection, but favipiravir was significantly more effective in reducing viral load and hospitalization rates. Furthermore, favipiravir caused significantly less side-effects than hydroxychloroquine.
References
Agrawal, Raju, Udwadia, Favipiravir: a new and emerging antiviral option in COVID-19, Med J Armed Forces India, doi:10.1016/j.mjafi.2020.08.004
Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering, doi:10.1016/j.eng.2020.03.007
Cap, Bilge, Isik, The effect of favipiravir on QTcinterval in patients hospitalized with coronavirus disease
Coomes, Haghbayan, Favipiravir, an antiviralfor COVID-19?, J Antimicrob Chemother, doi:10.1093/jac/dkaa171
Costanzo, Giglio, Roviello, SARS-CoV-2: recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus, Curr Med Chem, doi:10.2174/0929867327666200416131117
Covid-, This finding indicates that if SARS-CoV-2 PCR neg-284 ativity is expected, lost work time can be reduced. 285 The present study had some limitations. In order to make 286 a direct comparison of hydroxychloroquine and favipiravir 287 and to avoid bias, patients who received these agents in com-288 bination with other drugs
Doi, Hibino, Hase, A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19, Antimicrob Agents Chemother, doi:10.1128/AAC.01897-20
Elavarasi, Prasad, Seth, Chloroquine and hydroxychloroquine for the treatment of COVID-19: a systematic review and meta-analysis, J Gen Intern Med, doi:10.1007/s11606-020-06146-w
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B, doi:10.2183/pjab.93.027
Ghasemnejad-Berenji, Pashapour, Favipiravir and COVID-19: a simplified summary, Drug Res, doi:10.1055/a-1296-7935
Hernandez, Roman, Pasupuleti, Barboza, White, Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review, Ann Intern Med, doi:10.7326/M20-2496
Hu, Guo, Zhou, Shi, Characteristics of SARS-CoV-2 315 and COVID-19, Nat Rev Microbiol, doi:10.1038/s41579-020-00459-7
Ib Añez, Martínez, Valenzuela, Silva, Valenzuela, Hydroxychloroquineand chloroquine in COVID-19: should they be used as standard therapy?, Clin Rheumatol, doi:10.1007/s10067-020-05202-4
Izci-Cetinkaya, Karag€ Oz, Yildiz, Comparison of liver safety of favipiravir and hydroxychloroquine in COVID-19 treatment, Klimik Derg, doi:10.5152/kd.2020.49
Joshi, Parkar, Ansari, Role of favipiravir in the treatment of COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.10.069
Kaptein, Jacobs, Langendries, Favipiravir at highdoses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2014441117
Mehta, Mazer-Amirshahi, Alkindi, Pourmand, Pharmacotherapy in COVID-19; A narrative review for 319 emergency providers, Am J Emerg Med, doi:10.1016/j.ajem.2020.04.035
Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and metaanalysis, Virol J, doi:10.1186/s12985-020-01412-z
Sinha, Balayla, Hydroxychloroquine and COVID-19, Postgrad Med J, doi:10.1136/postgradmedj-2020-137785
Therefore, favipiravir is thought to be a useful agent in the 305 treatment of mild or moderate COVID-19 infection
Therefore, lost work time was 276 similar in patients who received hydroxychloroquine or favi-277 piravir
Yousefi, Valizadeh, Ghaffari, Vahedi, Karbalaei et al., A global treatments for coronaviruses including COVID-19, J Cell Physiol, doi:10.1002/jcp.29785
{ 'DOI': '10.1016/j.bjid.2022.102328', 'ISSN': ['1413-8670'], 'URL': 'http://dx.doi.org/10.1016/j.bjid.2022.102328', 'alternative-id': ['S1413867022000174'], 'article-number': '102328', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-7505-341X', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Turan', 'given': 'Derya Bayırlı', 'sequence': 'first'}, { 'ORCID': 'http://orcid.org/0000-0002-1193-2079', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Menteş', 'given': 'Mehtap', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-2621-1511', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Özel', 'given': 'Yıldıran', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-0585-8797', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Şerefhanoğlu', 'given': 'Kıvanç', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-7652-6880', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Aydoğan', 'given': 'Burcu', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-7838-7290', 'affiliation': [], 'authenticated-orcid': False, 'family': 'İbil', 'given': 'Neşe', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-5870-6426', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Güneşdoğdu', 'given': 'Füsun', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-2494-0083', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Orucova', 'given': 'Hijran Mammadova', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-7459-9210', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Saltürk', 'given': 'Cüneyt', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-0059-1667', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Çelik', 'given': 'Hakan', 'sequence': 'additional'}], 'container-title': ['The Brazilian Journal of Infectious Diseases'], 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T23:11:37Z', 'timestamp': 1643757097000}, 'deposited': { 'date-parts': [[2022, 2, 6]], 'date-time': '2022-02-06T12:43:59Z', 'timestamp': 1644151439000}, 'indexed': {'date-parts': [[2022, 2, 6]], 'date-time': '2022-02-06T13:11:16Z', 'timestamp': 1644153076304}, 'is-referenced-by-count': 0, 'issn-type': [{'type': 'print', 'value': '1413-8670'}], 'issued': {'date-parts': [[2022, 2]]}, 'language': 'en', 'license': [ { 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}}, { 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 1, 28]], 'date-time': '2022-01-28T00:00:00Z', 'timestamp': 1643328000000}}], 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1413867022000174?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1413867022000174?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'member': '78', 'original-title': [], 'page': '102328', 'prefix': '10.1016', 'published': {'date-parts': [[2022, 2]]}, 'published-print': {'date-parts': [[2022, 2]]}, 'publisher': 'Elsevier BV', 'reference': [ { 'DOI': '10.1038/s41579-020-00459-7', 'article-title': 'Characteristics of SARS-CoV-2 and COVID-19', 'author': 'Hu', 'doi-asserted-by': 'crossref', 'first-page': '141', 'journal-title': 'Nat Rev Microbiol', 'key': '10.1016/j.bjid.2022.102328_bib0001', 'volume': '19', 'year': '2021'}, { 'DOI': '10.1016/j.ajem.2020.04.035', 'article-title': 'Pharmacotherapy in COVID-19; A narrative review for emergency providers', 'author': 'Mehta', 'doi-asserted-by': 'crossref', 'first-page': '1488', 'journal-title': 'Am J Emerg Med', 'key': '10.1016/j.bjid.2022.102328_bib0002', 'volume': '38', 'year': '2020'}, { 'DOI': '10.1002/jcp.29785', 'article-title': 'A global treatments for coronaviruses including COVID-19', 'author': 'Yousefi', 'doi-asserted-by': 'crossref', 'first-page': '9133', 'journal-title': 'J Cell Physiol', 'key': '10.1016/j.bjid.2022.102328_bib0003', 'volume': '235', 'year': '2020'}, { 'DOI': '10.1136/postgradmedj-2020-137785', 'article-title': 'Hydroxychloroquine and COVID-19', 'author': 'Sinha', 'doi-asserted-by': 'crossref', 'first-page': '550', 'journal-title': 'Postgrad Med J', 'key': '10.1016/j.bjid.2022.102328_bib0004', 'volume': '96', 'year': '2020'}, { 'DOI': '10.1093/jac/dkaa171', 'article-title': 'Favipiravir, an antiviralfor COVID-19?', 'author': 'Coomes', 'doi-asserted-by': 'crossref', 'first-page': '2013', 'journal-title': 'J Antimicrob Chemother', 'key': '10.1016/j.bjid.2022.102328_bib0005', 'volume': '75', 'year': '2020'}, { 'DOI': '10.1007/s11606-020-06146-w', 'article-title': 'Chloroquine and hydroxychloroquine for the treatment of COVID-19: a ' 'systematic review and meta-analysis', 'author': 'Elavarasi', 'doi-asserted-by': 'crossref', 'first-page': '3308', 'journal-title': 'J Gen Intern Med', 'key': '10.1016/j.bjid.2022.102328_bib0006', 'volume': '35', 'year': '2020'}, { 'DOI': '10.1016/j.mjafi.2020.08.004', 'article-title': 'Favipiravir: a new and emerging antiviral option in COVID-19', 'author': 'Agrawal', 'doi-asserted-by': 'crossref', 'first-page': '370', 'journal-title': 'Med J Armed Forces India', 'key': '10.1016/j.bjid.2022.102328_bib0007', 'volume': '76', 'year': '2020'}, { 'DOI': '10.2174/0929867327666200416131117', 'article-title': 'SARS-CoV-2: recent reports on antiviral therapies based on ' 'lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, ' 'remdesivir, favipiravir and other drugs for the treatment of the new ' 'coronavirus', 'author': 'Costanzo', 'doi-asserted-by': 'crossref', 'first-page': '4536', 'journal-title': 'Curr Med Chem', 'key': '10.1016/j.bjid.2022.102328_bib0008', 'volume': '27', 'year': '2020'}, { 'DOI': '10.2183/pjab.93.027', 'article-title': 'Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase', 'author': 'Furuta', 'doi-asserted-by': 'crossref', 'first-page': '449', 'journal-title': 'Proc Jpn Acad Ser B', 'key': '10.1016/j.bjid.2022.102328_bib0009', 'volume': '93', 'year': '2017'}, { 'DOI': '10.1007/s10067-020-05202-4', 'article-title': 'Hydroxychloroquineand chloroquine in COVID-19: should they be used as ' 'standard therapy?', 'author': 'Ibáñez', 'doi-asserted-by': 'crossref', 'first-page': '2461', 'journal-title': 'Clin Rheumatol', 'key': '10.1016/j.bjid.2022.102328_bib0010', 'volume': '39', 'year': '2020'}, { 'DOI': '10.7326/M20-2496', 'article-title': 'Hydroxychloroquine or chloroquine for treatment or prophylaxis of ' 'COVID-19: a living systematic review', 'author': 'Hernandez', 'doi-asserted-by': 'crossref', 'first-page': '287', 'journal-title': 'Ann Intern Med', 'key': '10.1016/j.bjid.2022.102328_bib0011', 'volume': '173', 'year': '2020'}, { 'DOI': '10.1016/j.eng.2020.03.007', 'article-title': 'Experimental treatment with favipiravir for COVID-19: an open-label ' 'control study', 'author': 'Cai', 'doi-asserted-by': 'crossref', 'first-page': '1192', 'journal-title': 'Engineering', 'key': '10.1016/j.bjid.2022.102328_bib0012', 'volume': '6', 'year': '2020'}, { 'DOI': '10.1073/pnas.2014441117', 'article-title': 'Favipiravir at highdoses has potent antiviral activity in ' 'SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity', 'author': 'Kaptein', 'doi-asserted-by': 'crossref', 'first-page': '26955', 'journal-title': 'Proc Natl Acad Sci U S A', 'key': '10.1016/j.bjid.2022.102328_bib0013', 'volume': '117', 'year': '2020'}, { 'DOI': '10.1128/AAC.01897-20', 'article-title': 'A prospective, randomized, open-label trial of early versus late ' 'favipiravir therapy in hospitalized patients with COVID-19', 'author': 'Doi', 'doi-asserted-by': 'crossref', 'journal-title': 'Antimicrob Agents Chemother', 'key': '10.1016/j.bjid.2022.102328_bib0014', 'volume': '64', 'year': '2020'}, { 'DOI': '10.1055/a-1296-7935', 'article-title': 'Favipiravir and COVID-19: a simplified summary', 'author': 'Ghasemnejad-Berenji', 'doi-asserted-by': 'crossref', 'first-page': '166', 'journal-title': 'Drug Res', 'key': '10.1016/j.bjid.2022.102328_bib0015', 'volume': '71', 'year': '2021'}, { 'DOI': '10.1186/s12985-020-01412-z', 'article-title': 'Favipiravir versus other antiviral or standard of care for COVID-19 ' 'treatment: a rapid systematic review and meta-analysis', 'author': 'Shrestha', 'doi-asserted-by': 'crossref', 'first-page': '141', 'journal-title': 'Virol J', 'key': '10.1016/j.bjid.2022.102328_bib0016', 'volume': '17', 'year': '2020'}, { 'DOI': '10.1016/j.ijid.2020.10.069', 'article-title': 'Role of favipiravir in the treatment of COVID-19', 'author': 'Joshi', 'doi-asserted-by': 'crossref', 'first-page': '501', 'journal-title': 'Int J Infect Dis', 'key': '10.1016/j.bjid.2022.102328_bib0017', 'volume': '102', 'year': '2021'}, { 'DOI': '10.5152/kd.2020.49', 'article-title': 'Comparison of liver safety of favipiravir and hydroxychloroquine in ' 'COVID-19 treatment', 'author': 'Izci-Cetinkaya', 'doi-asserted-by': 'crossref', 'first-page': '235', 'journal-title': 'Klimik Derg', 'key': '10.1016/j.bjid.2022.102328_bib0018', 'volume': '33', 'year': '2020'}, { 'DOI': '10.1016/j.jelectrocard.2020.10.015', 'article-title': 'The effect of favipiravir on QTcinterval in patients hospitalized with ' 'coronavirus disease 2019', 'author': 'Cap', 'doi-asserted-by': 'crossref', 'first-page': '115', 'journal-title': 'J Electrocardiol', 'key': '10.1016/j.bjid.2022.102328_bib0019', 'volume': '63', 'year': '2020'}], 'reference-count': 19, 'references-count': 19, 'relation': {}, 'score': 1, 'short-container-title': ['The Brazilian Journal of Infectious Diseases'], 'short-title': [], 'source': 'Crossref', 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'subtitle': [], 'title': [ 'The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in ' 'COVID-19 in healthcare workers'], 'type': 'journal-article'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit